Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... they say, depends on having a supportive policy environment. Similarly, Genzyme Corporation's James A. Geraghty also calls for expanding the biotech industry's involvement in ...
2009 NOV 23 ... publicly traded and commercially operating companies like Novo Nordisk and SangStat/Genzyme, global leaders in biological therapies, diabetes, transplantation and other chronic ... International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com announced that it had made important ...
2009 NOV 9 ... Previously, Ms. Fanucci was vice president of corporate development and strategy at Genzyme Corporation, and prior to that, vice president and director at Arthur D. Little, Inc. ...
2009 NOV 16 ... is clear that significant changes will be outlined as a result. Keywords: Genzyme Corporation, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Therapy, Treatment. ...
2009 NOV 2 ... Most recently, Dr. Joshi was Vice President of US Medical Affairs and Operations at Genzyme Corporation. Brian Conner, Vice President Quality and Regulatory Affairs/ General ...
2009 NOV 9 ... Centocor Ortho Biotech Services, LLC, Ortho Biotech, a division of Janssen Cilag, and Genzyme Corporation. Visit ManagingMyeloma.com for more information and resources on the ...
2009 NOV 2 ... Inc.), have been added as low intensity treatment options and clofarabine (Clolar®, Genzyme Corporation) as intermediate intensity treatment option for patients with AML who are 60 years or ...
